|
1
|
Wang SH and Yu J: Structure-based design
for binding peptides in anti-cancer therapy. Biomaterials.
156:1–15. 2018. View Article : Google Scholar
|
|
2
|
Wang X, Zhang L, Ding N, Yang X, Zhang J,
He J, Li Z and Sun LQ: Identification and characterization of
DNAzymes targeting DNA methyltransferase I for suppressing bladder
cancer proliferation. Biochem Biophys Res Commun. 461:329–333.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ingram JR, Blomberg OS, Rashidian M, Ali
L, Garforth S, Fedorov E, Fedorov AA, Bonanno JB, Le Gall C,
Crowley S, et al: Anti-CTLA-4 therapy requires an Fc domain for
efficacy. Proc Natl Acad Sci USA. 115:3912–3917. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di JX and Zhang HY: C188-9 a
small-molecule STAT3 inhibitor, exerts an antitumor effect on head
and neck squamous cell carcinoma. Anticancer Drugs. 30:846–853.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brun S, Bassissi F, Serdjebi C, Novello M,
Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi
C, et al: GNS561, a new lysosomotropic small molecule, for the
treatment of intrahe-patic cholangiocarcinoma. Invest New Drugs.
37:1135–1145. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jahangirian H, Kalantari K, Izadiyan Z,
Rafiee-Moghaddam R, Shameli K and Webster TJ: A review of small
molecules and drug delivery applications using gold and iron
nanoparticles. Int J Nanomedicine. 14:1633–1657. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tyagi A, Tuknait A, Anand P, Gupta S,
Sharma M, Mathur D, Joshi A, Singh S, Gautam A and Raghava GP:
CancerPPD: A database of anticancer peptides and proteins. Nucleic
Acids Res. 43(Database Issue): D837–D843. 2015. View Article : Google Scholar :
|
|
8
|
Thundimadathil J: Cancer treatment using
peptides: Current therapies and future prospects. J Amino Acids.
2012:9673472012. View Article : Google Scholar
|
|
9
|
Vlieghe P, Lisowski V, Martinez J and
Khrestchatisky M: Synthetic therapeutic peptides: Science and
market. Drug Discov Today. 15:40–56. 2010. View Article : Google Scholar
|
|
10
|
Otvos L Jr: Peptide-based drug design:
Here and now. Methods Mol Biol. 494:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoskin DW and Ramamoorthy A: Studies on
anticancer activities of antimicrobial peptides. Biochim Biophys
Acta. 1778:357–375. 2008. View Article : Google Scholar
|
|
12
|
Rodrigues EG, Dobroff AS, Taborda CP and
Travassos LR: Antifungal and antitumor models of bioactive
protective peptides. An Acad Bras Cienc. 81:503–520. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Droin N, Hendra JB, Ducoroy P and Solary
E: Human defensins as cancer biomarkers and antitumour molecules. J
Proteomics. 72:918–927. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simons K and Ikonen E: How cells handle
cholesterol. Science. 290:1721–1726. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sok M, Sentjurc M and Schara M: Membrane
fluidity characteristics of human lung cancer. Cancer Lett.
139:215–220. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zwaal RF and Schroit AJ: Pathophysiologic
implications of membrane phospholipid asymmetry in blood cells.
Blood. 89:1121–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schweizer F: Cationic amphiphilic peptides
with cancer-selective toxicity. Eur J Pharmacol. 625:190–194. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Utsugi T, Schroit AJ, Connor J, Bucana CD
and Fidler IJ: Elevated expression of phosphatidylserine in the
outer membrane leaflet of human tumor cells and recognition by
activated human blood monocytes. Cancer Res. 51:3062–3066.
1991.PubMed/NCBI
|
|
19
|
Harris F, Dennison SR, Singh J and Phoenix
DA: On the selectivity and efficacy of defense peptides with
respect to cancer cells. Med Res Rev. 33:190–234. 2013. View Article : Google Scholar
|
|
20
|
Li G, Huang Y, Feng Q and Chen Y:
Tryptophan as a probe to study the anticancer mechanism of action
and specificity of alpha-helical anticancer peptides. Molecules.
19:12224–12241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marqus S, Pirogova E and Piva TJ:
Evaluation of the use of therapeutic peptides for cancer treatment.
J Biomed Sci. 24:212017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roudi R, Syn NL and Roudbary M:
Antimicrobial peptides as biologic and immunotherapeutic agents
against Cancer: A comprehensive overview. Front Immunol.
8:13202017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alves AC, Ribeiro D, Nunes C and Reis S:
Biophysics in cancer: The relevance of drug-membrane interaction
studies. Biochim Biophys Acta. 1858:2231–2244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaji-Hasegawa A and Tsujimoto M:
Asymmetric distribution of phospholipids in biomembranes. Biol
Pharm Bull. 29:1547–1553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clark MR: Flippin' lipids. Nat Immunol.
12:373–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deliconstantinos G: Physiological aspects
of membrane lipid fluidity in malignancy. Anticancer Res.
7:1011–1021. 1987.PubMed/NCBI
|
|
27
|
Ran S, Downes A and Thorpe PE: Increased
exposure of anionic phospholipids on the surface of tumor blood
vessels. Cancer Res. 62:6132–6140. 2002.PubMed/NCBI
|
|
28
|
Stafford JH and Thorpe PE: Increased
exposure of phosphati-dylethanolamine on the surface of tumor
vascular endothelium. Neoplasia. 13:299–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barcelo-Coblijn G, Martin ML, de Almeida
RF, Noguera-Salva MA, Marcilla-Etxenike A, Guardiola-Serrano F,
Lüth A, Kleuser B, Halver JE and Escribá PV: Sphingomyelin and
sphin-gomyelin synthase (SMS) in the malignant transformation of
glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci
USA. 108:19569–19574. 2011. View Article : Google Scholar
|
|
30
|
Preetha A, Huilgol N and Banerjee R:
Comparison of paclitaxel penetration in normal and cancerous
cervical model monolayer membranes. Colloids Surf B Biointerfaces.
53:179–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao L, Feng SS and Go ML: Investigation
of molecular interactions between paclitaxel and DPPC by Langmuir
film balance and differential scanning calorimetry. J Pharm Sci.
93:86–98. 2004. View Article : Google Scholar
|
|
32
|
Logozzi M, Spugnini E, Mizzoni D, Di Raimo
R and Fais S: Extracellular acidity and increased exosome release
as key phenotypes of malignant tumors. Cancer Metastasis Rev.
38:93–101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cardone RA, Casavola V and Reshkin SJ: The
role of disturbed pH dynamics and the Na+/H+ exchanger in
metastasis. Nat Rev Cancer. 5:786–795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jobin ML and Alves ID: On the importance
of electrostatic interactions between cell penetrating peptides and
membranes: A pathway toward tumor cell selectivity? Biochimie.
107:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peyressatre M, Prevel C, Pellerano M and
Morris MC: Targeting cyclin-dependent kinases in human cancers:
From small molecules to Peptide inhibitors. Cancers (Basel).
7:179–237. 2015. View Article : Google Scholar
|
|
36
|
Raucher D and Ryu JS: Cell-penetrating
peptides: Strategies for anticancer treatment. Trends Mol Med.
21:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li J, Tan S, Chen X, Zhang CY and Zhang Y:
Peptide aptamers with biological and therapeutic applications. Curr
Med Chem. 18:4215–4222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fuertes MA, Castilla J, Alonso C and Perez
JM: Cisplatin biochemical mechanism of action: from cytotoxicity to
induction of cell death through interconnections between apoptotic
and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Horwitz SB: Taxol (paclitaxel): Mechanisms
of action. Ann Oncol. 5(Suppl 6): S3–S6. 1994.PubMed/NCBI
|
|
40
|
Huang Y, Li X, Sha H, Zhang L, Bian X, Han
X and Liu B: Tumor-penetrating peptide fused to a pro-apoptotic
peptide facilitates effective gastric cancer therapy. Oncol Rep.
37:2063–2070. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang B, Shi W, Li J, Liao C, Yang L,
Huang W and Qian H: Synthesis and biological evaluation of novel
peptides based on antimicrobial peptides as potential agents with
antitumor and multidrug resistance-reversing activities. Chem Biol
Drug Des. 90:972–980. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ramsey JD and Flynn NH: Cell-penetrating
peptides transport therapeutics into cells. Pharmacol Ther.
154:78–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kapoor P, Singh H, Gautam A, Chaudhary K,
Kumar R and Raghava GP: TumorHoPe: A database of tumor homing
peptides. PLoS One. 7:e351872012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ghasemy S, Garcia-Pindado J, Aboutalebi F,
Dormiani K, Teixido M and Malakoutikhah M: Fine-tuning the
physicochemical properties of peptide-based blood-brain barrier
shuttles. Bioorg Med Chem. 26:2099–2106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Buckton LK and McAlpine SR: Improving the
cell permeability of polar cyclic peptides by replacing residues
with alkylated amino acids, asparagines, and d-Amino Acids. Org
Lett. 20:506–509. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Perry SR, Hill TA, de Araujo AD, Hoang HN
and Fairlie DP: Contiguous hydrophobic and charged surface patches
in short helix-constrained peptides drive cell permeability. Org
Biomol Chem. 16:367–371. 2018. View Article : Google Scholar
|
|
47
|
Shoombuatong W, Schaduangrat N and
Nantasenamat C: Unraveling the bioactivity of anticancer peptides
as deduced from machine learning. EXCLI J. 17:734–752.
2018.PubMed/NCBI
|
|
48
|
Dai YX, Cai XG, Shi W, Bi XZ, Su X, Pan
MB, Li HL, Lin HY, Huang WL and Qian H: Pro-apoptotic cationic host
defense peptides rich in lysine or arginine to reverse drug
resistance by disrupting tumor cell membrane. Amino Acids.
49:1601–1610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Navarro S, Aleu J, Jimenez M, Boix E,
Cuchillo CM and Nogues MV: The cytotoxicity of eosinophil cationic
protein/ribonuclease 3 on eukaryotic cell lines takes place through
its aggregation on the cell membrane. Cell Mol Life Sci.
65:324–337. 2008. View Article : Google Scholar
|
|
50
|
Midoux P, Kichler A, Boutin V, Maurizot JC
and Monsigny M: Membrane permeabilization and efficient gene
transfer by a peptide containing several histidines. Bioconjug
Chem. 9:260–267. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yamaguchi Y, Yamamoto K, Sato Y, Inoue S,
Morinaga T and Hirano E: Combination of aspartic acid and glutamic
acid inhibits tumor cell proliferation. Biomed Res. 37:153–159.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Oancea E, Teruel MN, Quest AF and Meyer T:
Green fluorescent protein (GFP)-tagged cysteine-rich domains from
protein kinase C as fluorescent indicators for diacylglycerol
signaling in living cells. J Cell Biol. 140:485–498. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shamova O, Orlov D, Stegemann C, Czihal P,
Hoffmann R, Brogden K, Kolodkin N, Sakuta G, Tossi A, Sahl HG, et
al: ChBac3.4: A Novel proline-rich antimicrobial peptide from goat
leukocytes. Int J Pept Res Ther. 15:107–119. 2009. View Article : Google Scholar
|
|
54
|
Maddocks ODK, Athineos D, Cheung EC, Lee
P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D,
Kruiswijk F, et al: Modulating the therapeutic response of tumours
to dietary serine and glycine starvation. Nature. 544:372–376.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kawaguchi K, Han Q, Li S, Tan Y, Igarashi
K, Kiyuna T, Miyake K, Miyake M, Chmielowski B, Nelson SD, et al:
Targeting methionine with oral recombinant methioninase (o-rMETase)
arrests a patient-derived orthotopic xenograft (PDOX) model of
BRAF-V600E mutant melanoma: Implications for chronic clinical
cancer therapy and prevention. Cell Cycle. 17:356–361. 2018.
View Article : Google Scholar :
|
|
56
|
Gueron G, Anselmino N, Chiarella P, Ortiz
EG, Lage Vickers S, Paez AV, Giudice J, Contin MD, Leonardi D,
Jaworski F, et al: Game-changing restraint of Ros-damaged
phenylalanine, upon tumor metastasis. Cell Death Dis. 9:1402018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dennison SR, Whittaker M, Harris F and
Phoenix DA: Anticancer alpha-helical peptides and
structure/function relationships underpinning their interactions
with tumour cell membranes. Curr Protein Pept Sci. 7:487–499. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Marchand C, Krajewski K, Lee HF, Antony S,
Johnson AA, Amin R, Roller P, Kvaratskhelia M and Pommier Y:
Covalent binding of the natural antimicrobial peptide indolicidin
to DNA abasic sites. Nucleic Acids Res. 34:5157–5165. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Barras D, Chevalier N, Zoete V, Dempsey R,
Lapouge K, Olayioye MA, Michielin O and Widmann C: A WXW motif is
required for the anticancer activity of the TAT-RasGAP317-326
peptide. J Biol Chem. 289:23701–23711. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ahmaditaba MA, Shahosseini S, Daraei B,
Zarghi A and Houshdar Tehrani MH: Design, synthesis, and biological
evaluation of new peptide analogues as selective cox-2 inhibitors.
Arch Pharm (Weinheim). 350:e17001582017. View Article : Google Scholar
|
|
61
|
Bhunia D, Mondal P, Das G, Saha A,
Sengupta P, Jana J, Mohapatra S, Chatterjee S and Ghosh S: Spatial
position regulates power of tryptophan: Discovery of a
major-groove-specific nuclear-localizing, cell-penetrating
tetrapeptide. J Am Chem Soc. 140:1697–1714. 2018. View Article : Google Scholar
|
|
62
|
Huang YB, Wang XF, Wang HY, Liu Y and Chen
Y: Studies on mechanism of action of anticancer peptides by
modulation of hydrophobicity within a defined structural framework.
Mol Cancer Ther. 10:416–426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang QZ, Wang C, Lang L, Zhou Y, Wang H
and Shang DJ: Design of potent, non-toxic anticancer peptides based
on the structure of the antimicrobial peptide, temporin-1CEa. Arch
Pharm Res. 36:1302–1310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dennison SR, Harris F, Bhatt T, Singh J
and Phoenix DA: A theoretical analysis of secondary structural
characteristics of anticancer peptides. Mol Cell Biochem.
333:129–135. 2010. View Article : Google Scholar
|
|
65
|
Wu JM, Jan PS, Yu HC, Haung HY, Fang HJ,
Chang YI, Cheng JW and Chen HM: Structure and function of a custom
anticancer peptide, CB1a. Peptides. 30:839–848. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lins L and Brasseur R: Tilted peptides: A
structural motif involved in protein membrane insertion? J Pept
Sci. 14:416–422. 2008. View Article : Google Scholar
|
|
67
|
Lins L, Decaffmeyer M, Thomas A and
Brasseur R: Relationships between the orientation and the
structural properties of peptides and their membrane interactions.
Biochim Biophys Acta. 1778:1537–1544. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R,
Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC Jr, Liao WS, et al:
Potent and selective phosphopeptide mimetic prodrugs targeted to
the Src homology 2 (SH2) domain of signal transducer and activator
of transcription 3. J Med Chem. 54:3549–3563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gabernet G, Gautschi D, Muller AT, Neuhaus
CS, Armbrecht L, Dittrich PS, Hiss JA and Schneider G: In silico
design and optimization of selective membranolytic anticancer
peptides. Sci Rep. 9:112822019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Singh M, Kumar V, Sikka K, Thakur R,
Harioudh MK, Mishra DP, Ghosh JK and Siddiqi MI: Computational
design of biologically active anticancer peptides and their
interactions with heterogeneous POPC/POPS Lipid membranes. J Chem
Inf Model. 60:332–341. 2020. View Article : Google Scholar
|
|
71
|
Ray T, Kar D and Pal A, Mukherjee S, Das C
and Pal A: Molecular targeting of breast and colon cancer cells by
PAR1 mediated apoptosis through a novel pro-apoptotic peptide.
Apoptosis. 23:679–694. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bohmova E, Machova D, Pechar M, Pola R,
Venclikova K, Janouskova O and Etrych T: Cell-penetrating peptides:
A useful tool for the delivery of various cargoes into cells.
Physiol Res. 67(Suppl 2): S267–S279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Levely ME, Mitchell MA and Nicholas JA:
Synthetic immunogens constructed from T-cell and B-cell stimulating
peptides (T:B chimeras): Preferential stimulation of unique T- and
B-cell specificities is influenced by immunogen configuration. Cell
Immunol. 125:65–78. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Asao T, Takahashi F and Takahashi K:
Resistance to molecu-larly targeted therapy in non-small-cell lung
cancer. Respir Investig. 57:20–26. 2019. View Article : Google Scholar
|
|
75
|
Zhang H, Han D, Lv T, Liu K, Yang Y, Xu X
and Chen Y: Novel peptide myristoly-CM4 induces selective
cytotoxicity in leukemia K562/MDR and Jurkat cells by necrosis
and/or apop-tosis pathway. Drug Des Devel Ther. 13:2153–2167. 2019.
View Article : Google Scholar :
|
|
76
|
Chen YQ, Min C, Sang M, Han YY, Ma X, Xue
XQ and Zhang SQ: A cationic amphiphilic peptide ABP-CM4 exhibits
selective cytotoxicity against leukemia cells. Peptides.
31:1504–1510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jiang R, Du X and Lonnerdal B: Comparison
of bioactivities of talactoferrin and lactoferrins from human and
bovine milk. J Pediatr Gastroenterol Nutr. 59:642–652. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tyagi A, Kapoor P, Kumar R, Chaudhary K,
Gautam A and Raghava GP: In silico models for designing and
discovering novel anticancer peptides. Sci Rep. 3:29842013.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hajisharifi Z, Piryaiee M, Mohammad Beigi
M, Behbahani M and Mohabatkar H: Predicting anticancer peptides
with Chou's pseudo amino acid composition and investigating their
muta-genicity via Ames test. J Theor Biol. 341:34–40. 2014.
View Article : Google Scholar
|
|
80
|
Chen W, Feng PM, Lin H and Chou KC:
iRSpot-PseDNC: Identify recombination spots with pseudo
dinucleotide composition. Nucleic Acids Res. 41:e682013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Grisoni F, Neuhaus C, Gabernet G, Muller
A, Hiss J and Schneider G: Designing anticancer peptides by
constructive machine learning. ChemMedChem. 13:1300–1302. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kozlowska K, Nowak J, Kwiatkowski B and
Cichorek M: ESR study of plasmatic membrane of the transplantable
melanoma cells in relation to their biological properties. Exp
Toxicol Pathol. 51:89–92. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Mai JC, Mi Z, Kim SH, Ng B and Robbins PD:
A proapoptotic peptide for the treatment of solid tumors. Cancer
Res. 61:7709–7712. 2001.PubMed/NCBI
|
|
84
|
Zhang W, Li J, Liu LW, Wang KR, Song JJ,
Yan JX, Li ZY, Zhang BZ and Wang R: A novel analog of antimicrobial
peptide Polybia-MPI, with thioamide bond substitution, exhibits
increased therapeutic efficacy against cancer and diminished
toxicity in mice. Peptides. 31:1832–1838. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sinthuvanich C, Veiga AS, Gupta K, Gaspar
D, Blumenthal R and Schneider JP: Anticancer β-hairpin peptides:
Membrane-induced folding triggers activity. J Am Chem Soc.
134:6210–6217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gaspar D, Veiga AS, Sinthuvanich C,
Schneider JP and Castanho MA: Anticancer peptide SVS-1: Efficacy
precedes membrane neutralization. Biochemistry. 51:6263–6265. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Negi B, Kumar D and Rawat DS: Marine
peptides as anticancer agents: A remedy to mankind by nature. Curr
Protein Pept Sci. 18:885–904. 2017. View Article : Google Scholar
|
|
88
|
Lemeshko VV: Electrical potentiation of
the membrane permeabilization by new peptides with anticancer
properties. Biochim Biophys Acta. 1828:1047–1056. 2013. View Article : Google Scholar
|
|
89
|
Liu X, Cao R, Wang S, Jia J and Fei H:
Amphipathicity determines different cytotoxic mechanisms of lysine-
or arginine-rich cationic hydrophobic peptides in cancer cells. J
Med Chem. 59:5238–5247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hu C, Chen X, Zhao W, Chen Y and Huang Y:
Design and modification of anticancer peptides. Drug Des.
5:1000138–1000147. 2016. View Article : Google Scholar
|
|
91
|
Boohaker RJ, Lee MW, Vishnubhotla P, Perez
JM and Khaled AR: The use of therapeutic peptides to target and to
kill cancer cells. Curr Med Chem. 19:3794–3804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bidwell GL III and Raucher D: Therapeutic
peptides for cancer therapy. Part I-peptide inhibitors of signal
transduction cascades. Expert Opin Drug Deliv. 6:1033–1047. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Raucher D, Moktan S, Massodi I and Bidwell
GL III: Therapeutic peptides for cancer therapy. Part II-cell cycle
inhibitory peptides and apoptosis-inducing peptides. Expert Opin
Drug Deliv. 6:1049–1064. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ulasov IV, Borovjagin AV, Timashev P,
Cristofanili M and Welch DR: KISS1 in breast cancer progression and
autophagy. Cancer Metastasis Rev. 38:493–506. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lamidi OF, Sani M, Lazzari P, Zanda M and
Fleming IN: The tubulysin analogue KEMTUB10 induces apoptosis in
breast cancer cells via p53, Bim and Bcl-2. J Cancer Res Clin
Oncol. 141:1575–1583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang C, Chen YW, Zhang L, Gong XG, Zhou Y
and Shang DJ: Melanoma cell surface-expressed phosphatidylserine as
a therapeutic target for cationic anticancer peptide,
temporin-1CEa. J Drug Target. 24:548–556. 2016. View Article : Google Scholar
|
|
97
|
Cao XW, Yang XZ, Du X, Fu LY, Zhang TZ,
Shan HW, Zhao J and Wang FJ: Structure optimisation to improve the
delivery efficiency and cell selectivity of a tumour-targeting
cell-penetrating peptide. J Drug Target. 26:777–792. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Shull AY, Hu CA and Teng Y: Zebrafish as a
model to evaluate peptide-related cancer therapies. Amino Acids.
49:1907–1913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Leite ML, da Cunha NB and Costa FF:
Antimicrobial peptides, nanotechnology, and natural metabolites as
novel approaches for cancer treatment. Pharmacol Ther. 183:160–176.
2018. View Article : Google Scholar
|
|
100
|
Sun T, Zhang YS, Pang B, Hyun DC, Yang M
and Xia Y: Engineered nanoparticles for drug delivery in cancer
therapy. Angew Chem Int Ed Engl. 53:12320–12364. 2014.PubMed/NCBI
|
|
101
|
Dossa F, Acuna SA, Rickles AS, Berho M,
Wexner SD, Quereshy FA, Baxter NN and Chadi SA: Association between
adjuvant chemotherapy and overall survival in patients with rectal
cancer and pathological complete response after neoadjuvant
chemotherapy and resection. JAMA Oncol. 4:930–937. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xu J, Khan AR, Fu M, Wang R, Ji J and Zhai
G: Cell-penetrating peptide: A means of breaking through the
physiological barriers of different tissues and organs. J Control
Release. 309:106–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Duarte D, Fraga AG, Pedrosa J, Martel F
and Vale N: Increasing the potential of cell-penetrating peptides
for cancer therapy using a new pentagonal scaffold. Eur J
Pharmacol. 860:1725542019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Park SE, Sajid MI, Parang K and Tiwari RK:
Cyclic cell-penetrating peptides as efficient intracellular drug
delivery tools. Mol Pharm. 16:3727–3743. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Copolovici DM, Langel K, Eriste E and
Langel U: Cell-penetrating peptides:Design, synthesis, and
applications. ACS Nano. 8:1972–1994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Rothbard JB, Jessop TC, Lewis RS, Murray
BA and Wender PA: Role of membrane potential and hydrogen bonding
in the mechanism of translocation of guanidinium-rich peptides into
cells. J Am Chem Soc. 126:9506–9507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Guidotti G, Brambilla L and Rossi D:
Cell-penetrating peptides: From basic research to clinics. Trends
Pharmacol Sci. 38:406–424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Pujals S and Giralt E: Proline-rich,
amphipathic cell-penetrating peptides. Adv Drug Deliv Rev.
60:473–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Marks JR, Placone J, Hristova K and Wimley
WC: Spontaneous membrane-translocating peptides by orthogonal
high-throughput screening. J Am Chem Soc. 133:8995–9004. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Koren E and Torchilin VP: Cell-penetrating
peptides: Breaking through to the other side. Trends Mol Med.
18:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kamei N, Onuki Y, Takayama K and
Takeda-Morishita M: Mechanistic study of the uptake/permeation of
cell-penetrating peptides across a caco-2 monolayer and their
stimulatory effect on epithelial insulin transport. J Pharm Sci.
102:3998–4008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chen Y, Xie X, Wu A, Wang L, Hu Y, Zhang H
and Li Y: A synthetic cell-penetrating peptide derived from nuclear
localization signal of EPS8 exerts anticancer activity against
acute myeloid leukemia. J Exp Clin Cancer Res. 37:122018.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lyu L, Huang LQ, Huang T, Xiang W, Yuan JD
and Zhang CH: Cell-penetrating peptide conjugates of gambogic acid
enhance the antitumor effect on human bladder cancer EJ cells
through ROS-mediated apoptosis. Drug Des Devel Ther. 12:743–756.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Benergossi J, Calixto G, Fonseca-Santos B,
Aida KL, de Cassia Negrini T, Duque C, Gremiao MP and Chorilli M:
Highlights in peptide nanoparticle carriers intended to oral
diseases. Curr Top Med Chem. 15:345–355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Meng F, Han N and Yeo Y: Organic
nanoparticle systems for spatiotemporal control of multimodal
chemotherapy. Expert Opin Drug Deliv. 14:427–446. 2017. View Article : Google Scholar :
|
|
116
|
Conibear AC, Schmid A, Kamalov M, Becker
CFW and Bello C: Recent advances in peptide-based approaches for
cancer treatment. Curr Med Chem. 27:1174–1205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Asadzadeh Z, Mohammadi H, Safarzadeh E,
Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, Azizi G and
Baradaran B: The paradox of Th17 cell functions in tumor immunity.
Cell Immunol. 322:15–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Darabi A, Thuring C and Paulsson KM: HLA-I
antigen presentation and tapasin influence immune responses against
malignant brain tumors-considerations for successful immunotherapy.
Anticancer Agents Med Chem. 14:1094–1100. 2014. View Article : Google Scholar
|
|
119
|
Li M, Shi HS, Zhang HL, Luo ZC, Wan Y, Lu
L, Luo ST and Yang L: bFGF peptide combined with the pVAX-8CpG
plasmid as adjuvant is a novel anticancer vaccine inducing
effective immune responses against Lewis lung carcinoma. Mol Med
Rep. 5:625–630. 2012. View Article : Google Scholar
|
|
120
|
Wang W, Li Y, Wang Y, Ren S, Li Y and Wang
B: Polyactin A is a novel and potent immunological adjuvant for
peptide-based cancer vaccine. Int Immunopharmacol. 54:95–102. 2018.
View Article : Google Scholar
|
|
121
|
Jin H, Wan C, Zou Z, Zhao G, Zhang L, Geng
Y, Chen T, Huang A, Jiang F, Feng JP, et al: Tumor ablation and
therapeutic immunity induction by an injectable peptide hydrogel.
ACS Nano. 12:3295–3310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Kakwere H, Ingham ES, Allen R, Mahakian
LM, Tam SM, Zhang H, Silvestrini MT, Lewis JS and Ferrara KW:
Toward personalized peptide-based cancer nanovaccines: A facile and
versatile synthetic approach. Bioconjug Chem. 28:2756–2771. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Apostolopoulos V and McKenzie IF: Cellular
mucins: Targets for immunotherapy. Crit Rev Immunol. 14:293–309.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Obara W, Eto M, Mimata H, Kohri K,
Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, et al: A
phase I/II study of cancer peptide vaccine S-288310 in patients
with advanced urothelial carcinoma of the bladder. Ann Oncol.
28:798–803. 2017. View Article : Google Scholar
|
|
125
|
Antonilli M, Rahimi H, Visconti V,
Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G,
Iadarola R, Pierelli L, et al: Triple peptide vaccination as
consolidation treatment in women affected by ovarian and breast
cancer: Clinical and immunological data of a phase I/II clinical
trial. Int J Oncol. 48:1369–1378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Asahara S, Takeda K, Yamao K, Maguchi H
and Yamaue H: Phase I/II clinical trial using HLA-A24-restricted
peptide vaccine derived from KIF20A for patients with advanced
pancreatic cancer. J Transl Med. 11:2912013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Rausch S, Gouttefangeas C, Hennenlotter J,
Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja
H, Frick A, et al: Results of a Phase 1/2 Study in Metastatic Renal
Cell Carcinoma Patients Treated with a Patient-specific Adjuvant
Multi-peptide Vaccine after Resection of Metastases. Eur Urol
Focus. 5:604–607. 2019. View Article : Google Scholar
|
|
128
|
Dutoit V, Migliorini D, Ranzanici G,
Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker
PR, Okada H, et al: Antigenic expression and spontaneous immune
responses support the use of a selected peptide set from the IMA950
glio-blastoma vaccine for immunotherapy of grade II and III glioma.
Oncoimmunology. 7:e13919722018. View Article : Google Scholar
|
|
129
|
Lilleby W, Gaudernack G, Brunsvig PF,
Vlatkovic L, Schulz M, Mills K, Hole KH and Inderberg EM: Phase
I/IIa clinical trial of a novel hTERT peptide vaccine in men with
metastatic hormone-naive prostate cancer. Cancer Immunol
Immunother. 66:891–901. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Talebi S, Bolhassani A, Azad TM, Arashkia
A and Modaresi MH: Immuno-stimulating peptide derived from HMGB1 is
more effective than the N-terminal domain of Gp96 as an endogenous
adjuvant for improvement of protein vaccines. Protein Pept Lett.
24:190–196. 2017. View Article : Google Scholar
|
|
131
|
Glover S, Delaney M, Dematte C, Kornberg
L, Frasco M, Tran-Son-Tay R and Benya RV: Phosphorylation of focal
adhesion kinase tyrosine 397 critically mediates gastrin-releasing
peptide's morphogenic properties. J Cell Physiol. 199:77–88. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Schally AV, Zhang X, Cai R, Hare JM,
Granata R and Bartoli M: Actions and potential therapeutic
applications of growth hormone-releasing hormone agonists.
Endocrinology. 160:1600–1612. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Munoz-Moreno L, Bajo AM, Prieto JC and
Carmena MJ: Growth hormone-releasing hormone (GHRH) promotes
metastatic phenotypes through EGFR/HER2 transactivation in prostate
cancer cells. Mol Cell Endocrinol. 446:59–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Jimenez JJ, DelCanto GM, Popovics P, Perez
A, Vila Granda A, Vidaurre I, Cai RZ, Rick FG, Swords RT and
Schally AV: A new approach to the treatment of acute myeloid
leukaemia targeting the receptor for growth hormone-releasing
hormone. Br J Haematol. 181:476–485. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Chin YT, Wang LM, Hsieh MT, Shih YJ, Nana
AW, Changou CA, Yang YSH, Chiu HC, Fu E, Davis PJ, et al: Leptin
OB3 peptide suppresses leptin-induced signaling and progression in
ovarian cancer cells. J Biomed Sci. 24:512017. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Zhang M, Zhang M, Wang J, Cai Q, Zhao R,
Yu Y, Tai H, Zhang X and Xu C: Retro-inverso follicle-stimulating
hormone peptide-mediated polyethylenimine complexes for targeted
ovarian cancer gene therapy. Drug Deliv. 25:995–1003. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sogaard CK, Moestue SA, Rye MB, Kim J,
Nepal A, Liabakk NB, Bachke S, Bathen TF, Otterlei M and Hill DK:
APIM-peptide targeting PCNA improves the efficacy of docetaxel
treatment in the TRAMP mouse model of prostate cancer. Oncotarget.
9:11752–11766. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Farokhzad OC and Langer R: Impact of
nanotechnology on drug delivery. ACS Nano. 3:16–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Liu X, Peng J, He J, Li Q, Zhou J, Liang X
and Tang S: Selection and identification of novel peptides
specifically targeting human cervical cancer. Amino Acids.
50:577–592. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Serrill JD, Wan X, Hau AM, Jang HS,
Coleman DJ, Indra AK, Alani AW, McPhail KL and Ishmael JE:
Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2
expression and suppresses tumor growth in glioblastoma xenografts.
Invest New Drugs. 34:24–40. 2016. View Article : Google Scholar
|
|
141
|
Chakrabarti S, Guha S and Majumder K:
Food-derived bioac-tive peptides in human health: Challenges and
opportunities. Nutrients. 10:17382018. View Article : Google Scholar
|
|
142
|
Sable R, Parajuli P and Jois S: Peptides,
Peptidomimetics, and polypeptides from marine sources: A wealth of
natural sources for pharmaceutical applications. Mar Drugs.
15:1242017. View Article : Google Scholar :
|
|
143
|
O'Brien-Simpson NM, Hoffmann R, Chia CSB
and Wade JD: Editorial: Antimicrobial and Anticancer Peptides.
Front Chem. 6:132018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Sultan S, Huma N, Butt MS, Aleem M and
Abbas M: Therapeutic potential of dairy bioactive peptides: A
contemporary perspective. Crit Rev Food Sci Nutr. 58:105–115. 2018.
View Article : Google Scholar
|
|
145
|
Felicio MR, Silva ON, Goncalves S, Santos
NC and Franco OL: Peptides with dual antimicrobial and anticancer
activities. Front Chem. 5:52017. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Mohanty DP, Mohapatra S, Misra S and Sahu
PS: Milk derived bioactive peptides and their impact on human
health-A review. Saudi J Biol Sci. 23:577–583. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Gonzalez-Montoya M, Hernandez-Ledesma B,
Silvan JM, Mora-Escobedo R and Martinez-Villaluenga C: Peptides
derived from in vitro gastrointestinal digestion of germinated
soybean proteins inhibit human colon cancer cells proliferation and
inflammation. Food Chem. 242:75–82. 2018. View Article : Google Scholar
|
|
148
|
Prateep A, Sumkhemthong S, Suksomtip M,
Chanvorachote P and Chaotham C: Peptides extracted from edible
mushroom: Lentinus squarrosulus induces apoptosis in human lung
cancer cells. Pharm Biol. 55:1792–1799. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the last 25 years. J Nat Prod.
70:461–477. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Fahs S, Patil-Sen Y and Snape TJ:
Foldamers as anticancer therapeutics: Targeting protein-protein
interactions and the cell membrane. Chembiochem. 16:1840–1853.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Dhar A, Mallick S, Ghosh P, Maiti A, Ahmed
I, Bhattacharya S, Mandal T, Manna A, Roy K, Singh S, et al:
Simultaneous inhibition of key growth pathways in melanoma cells
and tumor regression by a designed bidentate constrained helical
peptide. Biopolymers. 102:344–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Tanishiki N, Yano Y and Matsuzaki K:
Endowment of pH responsivity to anticancer peptides by introducing
2,3-diami-nopropionic acid residues. Chembiochem. 20:2109–2117.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Dennison SR, Harris F, Mura M and Phoenix
DA: An atlas of anionic antimicrobial peptides from amphibians.
Curr Protein Pept Sci. 19:823–838. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Khamessi O, Ben Mabrouk H, ElFessi-Magouri
R and Kharrat R: RK1, the first very short peptide from Buthus
occi-tanus tunetanus inhibits tumor cell migration, proliferation
and angiogenesis. Biochem Biophys Res Commun. 499:1–7. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Choi YJ, Park SJ, Park YS, Park HS, Yang
KM and Heo K: EpCAM peptide-primed dendritic cell vaccination
confers significant anti-tumor immunity in hepatocellular carcinoma
cells. PLoS One. 13:e01906382018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Matsueda S, Itoh K and Shichijo S:
Antitumor activity of antibody against cytotoxic T lymphocyte
epitope peptide of lymphocyte-specific protein tyrosine kinase.
Cancer Sci. 109:611–617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Peng X, Zhou C, Hou X, Liu Y, Wang Z, Peng
X, Zhang Z, Wang R and Kong D: Molecular characterization and
bioactivity evaluation of two novel bombinin peptides from the skin
secretion of Oriental fire-bellied toad, Bombina orientalis. Amino
Acids. 50:241–253. 2018. View Article : Google Scholar
|
|
158
|
Xie X, Zhou W, Hu Y, Chen Y, Zhang H and
Li Y: A dual-function epidermal growth factor receptor pathway
substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T
lymphocyte-activating effect and a specific inhibitory activity.
Cell Death Dis. 9:3792018. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Wu ZZ, Ding GF, Huang FF, Yang ZS, Yu FM,
Tang YP, Jia YL, Zheng YY and Chen R: Anticancer activity of
anthopleura anjunae oligopeptides in prostate cancer DU-145 cells.
Mar Drugs. 16:pii: E125. 2018. View Article : Google Scholar
|
|
160
|
Shen Y, Maupetit J, Derreumaux P and
Tuffery P: Improved PEP-FOLD approach for peptide and miniprotein
structure prediction. J Chem Theory Comput. 10:4745–4758. 2014.
View Article : Google Scholar
|
|
161
|
Thevenet P, Shen Y, Maupetit J, Guyon F,
Derreumaux P and Tuffery P: PEP-FOLD: An updated de novo structure
prediction server for both linear and disulfide bonded cyclic
peptides. Nucleic Acids Res. 40:W288–W293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Hao Y, Yang N, Teng D, Wang X, Mao R and
Wang J: A review of the design and modification of lactoferricins
and their derivatives. Biometals. 31:331–341. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Dathe M, Schumann M, Wieprecht T, Winkler
A, Beyermann M, Krause E, Matsuzaki K, Murase O and Bienert M:
Peptide helicity and membrane surface charge modulate the balance
of electrostatic and hydrophobic interactions with lipid bilayers
and biological membranes. Biochemistry. 35:12612–12622. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Sun S, Zhao G, Huang Y, Cai M, Yan Q, Wang
H and Chen Y: Enantiomeric effect of d-Amino acid substitution on
the mechanism of action of α-helical membrane-active peptides. Int
J Mol Sci. 19:672017. View Article : Google Scholar
|
|
165
|
Hicks RP: Antibacterial and anticancer
activity of a series of novel peptides incorporating cyclic
tetra-substituted C(α) amino acids. Bioorg Med Chem. 24:4056–4065.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhou J, Yang X, Zhang W, Wang J, Wei C, Gu
F, Lei T and Qin Y: Construction of an Anticancer Fusion Peptide
(ACFP) derived from milk proteins and an assay of anti-ovarian
cancer cells in vitro. Anticancer Agents Med Chem. 17:635–643.
2017. View Article : Google Scholar
|
|
167
|
Bracci L, Mandarini E, Brunetti J, Depau
L, Pini A, Terzuoli L, Scali S and Falciani C: The GAG-specific
branched peptide NT4 reduces angiogenesis and invasiveness of tumor
cells. PLoS One. 13:e01947442018. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Chu HL, Yip BS, Chen KH, Yu HY, Chih YH,
Cheng HT, Chou YT and Cheng JW: Novel antimicrobial peptides with
high anticancer activity and selectivity. PLoS One.
10:e01263902015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
He B, Yang D, Qin M, Zhang Y, He B, Dai W,
Wang X, Zhang Q, Zhang H and Yin C: Increased cellular uptake of
peptide-modified PEGylated gold nanoparticles. Biochem Biophys Res
Commun. 494:339–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Tsuchiya N, Hosono A, Yoshikawa T, Shoda
K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H,
et al: Phase I study of glypican-3-derived peptide vaccine therapy
for patients with refractory pediatric solid tumors.
Oncoimmunology. 7:e13778722017. View Article : Google Scholar
|
|
171
|
Liang AL, Qian HL, Zhang TT, Zhou N, Wang
HJ, Men XT, Qi W, Zhang PP, Fu M, Liang X, et al: Bifunctional
fused polypeptide inhibits the growth and metastasis of breast
cancer. Drug Des Devel Ther. 9:5671–5686. 2015.PubMed/NCBI
|
|
172
|
Herbert KJ, Ashton TM, Prevo R, Pirovano G
and Higgins GS: T-LAK cell-originated protein kinase (TOPK): An
emerging target for cancer-specific therapeutics. Cell Death Dis.
9:10892018. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Wu D, Gao Y, Qi Y, Chen L, Ma Y and Li Y:
Peptide-based cancer therapy: Opportunity and challenge. Cancer
Lett. 351:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zachos I, Konstantinopoulos PA, Tzortzis
V, Gravas S, Karatzas A, Karamouzis MV, Melekos M and Papavassiliou
AG: Systemic therapy of metastatic bladder cancer in the molecular
era: Current status and future promise. Expert Opin Investig Drugs.
19:875–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Amir E, Hughes S, Blackhall F, Thatcher N,
Ostoros G, Timar J, Tovari J, Kovacs G and Dome B: Targeting blood
vessels for the treatment of non-small cell lung cancer. Curr
Cancer Drug Targets. 8:392–403. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Kim-Schulze S, Taback B and Kaufman HL:
Cytokine therapy for cancer. Surg Oncol Clin N Am. 16:793–818.
viii2007. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Niu F, Yan J, Ma B, Li S, Shao Y, He P,
Zhang W, He W, Ma PX and Lu W: Lanthanide-doped nanoparticles
conjugated with an anti-CD33 antibody and a p53-activating peptide
for acute myeloid leukemia therapy. Biomaterials. 167:132–142.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Vats K, Sharma R, Sarma HD, Satpati D and
Dash A: 68Ga-labeled HBED-CC variant of uPAR targeting
peptide AE105 compared with 68Ga-NODAGA-AE105. Anticancer Agents
Med Chem. 18:1289–1294. 2018. View Article : Google Scholar
|
|
179
|
Ahmadpour S, Noaparast Z, Abedi SM and
Hosseinimehr SJ: 99mTc-(tricine)-HYNIC-Lys-FROP peptide for breast
tumor targeting. Anticancer Agents Med Chem. 18:1295–1302. 2018.
View Article : Google Scholar
|
|
180
|
Zhang J, Spring H and Schwab M:
Neuroblastoma tumor cell-binding peptides identified through random
peptide phage display. Cancer Lett. 171:153–164. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Soudy R, Etayash H, Bahadorani K,
Lavasanifar A and Kaur K: Breast cancer targeting peptide binds
keratin 1: A new molecular marker for targeted drug delivery to
breast cancer. Mol Pharm. 14:593–604. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Du Y, Wang L, Wang W, Guo T, Zhang M,
Zhang P, Zhang Y, Wu K, Li A, Wang X, et al: Novel application of
cell penetrating R11 peptide for diagnosis of bladder cancer. J
Biomed Nanotechnol. 14:161–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Sato S, Nakamura T, Katagiri T, Tsuchikawa
T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H,
et al: Molecular targeting of cell-permeable peptide inhibits
pancreatic ductal adeno-carcinoma cell proliferation. Oncotarget.
8:113662–113672. 2017. View Article : Google Scholar
|
|
184
|
Kang T, Huang Y, Zhu Q, Cheng H, Pei Y,
Feng J, Xu M, Jiang G, Song Q, Jiang T, et al: Necroptotic cancer
cells-mimicry nanovaccine boosts anti-tumor immunity with tailored
immune-stimulatory modality. Biomaterials. 164:80–97. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Garay H, Espinosa LA, Perera Y, Sanchez A,
Diago D, Perea SE, Besada V, Reyes O and Gonzalez LJ:
Characterization of low-abundance species in the active
pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer
synthetic peptide. J Pept Sci. 24:e30812018. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Perea SE, Reyes O, Baladron I, Perera Y,
Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, et
al: CIGB-300, a novel proapoptotic peptide that impairs the CK2
phosphorylation and exhibits anticancer properties both in vitro
and in vivo. Mol Cell Biochem. 316:163–167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Rodriguez-Ulloa A, Ramos Y, Gil J, Perera
Y, Castellanos-Serra L, Garcia Y, Betancourt L, Besada V, Gonzalez
LJ, Fernandez-de-Cossio J, et al: Proteomic profile regulated by
the anticancer peptide CIGB-300 in non-small cell lung cancer
(NSCLC) cells. J Proteome Res. 9:5473–5483. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Hirabayashi K, Yanagisawa R, Saito S,
Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa
Y, et al: Feasibility and immune response of WT1 peptide
vaccination in combination with OK-432 for paediatric solid tumors.
Anticancer Res. 38:2227–2234. 2018.PubMed/NCBI
|
|
189
|
Yanagisawa R, Koizumi T, Koya T, Sano K,
Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H and Shimodaira
S: WT1-pulsed dendritic cell vaccine combined with chemotherapy for
resected pancreatic cancer in a phase I study. Anticancer Res.
38:2217–2225. 2018.PubMed/NCBI
|
|
190
|
Ohno S, Takano F, Ohta Y, Kyo S, Myojo S,
Dohi S, Sugiyama H, Ohta T and Inoue M: Frequency of myeloid
dendritic cells can predict the efficacy of Wilms' tumor 1 peptide
vaccination. Anticancer Res. 31:2447–2452. 2011.PubMed/NCBI
|
|
191
|
Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki
J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, et al:
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological
malignancy. Anticancer Res. 29:4779–4784. 2009.PubMed/NCBI
|
|
192
|
Ishikawa H, Imano M, Shiraishi O, Yasuda
A, Peng YF, Shinkai M, Yasuda T, Imamoto H and Shiozaki H: Phase I
clinical trial of vaccination with LY6K-derived peptide in patients
with advanced gastric cancer. Gastric Cancer. 17:173–180. 2014.
View Article : Google Scholar
|
|
193
|
Vasef MA, Ross JS and Cohen MB: Telomerase
activity in human solid tumors. Diagnostic utility and clinical
applications. Am J Clin Pathol. 112(1 Suppl): S68–S75.
1999.PubMed/NCBI
|
|
194
|
Bernhardt SL, Gjertsen MK, Trachsel S,
Moller M, Eriksen JA, Meo M, Buanes T and Gaudernack G: Telomerase
peptide vaccination of patients with non-resectable pancreatic
cancer: A dose escalating phase I/II study. Br J Cancer.
95:1474–1482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Kokhaei P, Palma M, Hansson L, Osterborg
A, Mellstedt H and Choudhury A: Telomerase (hTERT 611-626) serves
as a tumor antigen in B-cell chronic lymphocytic leukemia and
generates spontaneously antileukemic, cytotoxic T cells. Exp
Hematol. 35:297–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Aspeslagh S, Awada A, Matos-Pita A,
Aftimos P, Bahleda R, Varga A and Soria JC: Phase I dose-escalation
study of plitidepsin in combination with bevacizumab in patients
with refractory solid tumors. Anticancer Drugs. 27:1021–1027. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Engel JB, Tinneberg HR, Rick FG, Berkes E
and Schally AV: Targeting of peptide cytotoxins to LHRH receptors
for treatment of cancer. Curr Drug Targets. 17:488–494. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Noguchi M, Matsumoto K, Uemura H, Arai G,
Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, et al: An
open-label, randomized phase II trial of personalized peptide
vaccination in patients with bladder cancer that progressed after
platinum-based chemotherapy. Clin Cancer Res. 22:54–60. 2016.
View Article : Google Scholar
|
|
199
|
Toh U, Saku S, Okabe M, Iwakuma N,
Kimitsuki Y, Akashi M, Ogo E, Yamada A, Shichijo S, Itoh K, et al:
Development of peptide vaccines for triple-negative breast cancer
treatment. Gan To Kagaku Ryoho. 43:1249–1251. 2016.In Japanese.
PubMed/NCBI
|
|
200
|
Brown TA, Byrd K, Vreeland TJ, Clifton GT,
Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, et
al: Final analysis of a phase I/IIa trial of the folate-binding
protein-derived E39 peptide vaccine to prevent recurrence in
ovarian and endometrial cancer patients. Cancer Med. 8:4678–4687.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Schwartzentruber DJ, Lawson DH, Richards
JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K,
Pockaj B, et al: gp100 peptide vaccine and interleukin-2 in
patients with advanced melanoma. N Engl J Med. 364:2119–2127. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Mikecin AM, Walker LR, Kuna M and Raucher
D: Thermally targeted p21 peptide enhances bortezomib cytotoxicity
in androgen-independent prostate cancer cell lines. Anticancer
Drugs. 25:189–199. 2014. View Article : Google Scholar
|
|
203
|
Korani M, Korani S, Zendehdel E, Nikpoor
AR, Jaafari MR, Orafai HM, Johnston TP and Sahebkar A: Enhancing
the therapeutic efficacy of bortezomib in cancer therapy using
polymeric nanostructures. Curr Pharm Des. 25:4883–4892. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Zhou Y, Liu X, Xue J, Liu L, Liang T, Li
W, Yang X, Hou X and Fang H: Discovery of peptide boronate
derivatives as histone deacetylase and proteasome dual inhibitors
for overcoming bortezomib resistance of multiple myeloma. J Med
Chem. 63:4701–4715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Garofalo M, Grazioso G, Cavalli A and
Sgrignani J: How computational chemistry and drug delivery
techniques can support the development of new anticancer drugs.
Molecules. 25:17562020. View Article : Google Scholar :
|
|
206
|
Adlakha S, Sharma A, Vaghasiya K, Ray E
and Verma RK: Inhalation delivery of host defence peptides (HDP)
using nano-formulation strategies: A pragmatic approach for therapy
of pulmonary ailments. Curr Protein Pept Sci. 21:369–378. 2020.
View Article : Google Scholar
|
|
207
|
Tu Y, Tao J, Wang F, Liu P, Han Z, Li Z,
Ma Y and Gu Y: A novel peptide targeting gastrin releasing peptide
receptor for pancreatic neoplasm detection. Biomater Sci.
8:2682–2693. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Ohana J, Sandler U, Kass G, Stemmer SM and
Devary Y: dTCApFs, a derivative of a novel human hormone peptide,
induces apoptosis in cancer cells through a mechanism involving
loss of Golgi function. Mol Clin Oncol. 7:991–999. 2017.PubMed/NCBI
|
|
209
|
Stemmer SM, Benjaminov O, Silverman MH,
Sandler U, Purim O, Sender N, Meir C, Oren-Apoteker P, Ohana J and
Devary Y: A phase I clinical trial of dTCApFs, a derivative of a
novel human hormone peptide, for the treatment of
advanced/metastatic solid tumors. Mol Clin Oncol. 8:22–29.
2018.PubMed/NCBI
|
|
210
|
Murali R and Kieber-Emmons T: Cancer
immunotherapeutics: Evolution of monoclonal antibodies to peptide
immunogens. Monoclon Antib Immunodiagn Immunother. 33:179–182.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Tan Z and Zhang S: Past, present, and
future of targeting ras for cancer therapies. Mini Rev Med Chem.
16:345–357. 2016. View Article : Google Scholar
|
|
212
|
Li QX, Yu DH, Liu G, Ke N, McKelvy J and
Wong-Staal F: Selective anticancer strategies via intervention of
the death pathways relevant to cell transformation. Cell Death
Differ. 15:1197–1210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Micale N, Scarbaci K, Troiano V, Ettari R,
Grasso S and Zappala M: Peptide-based proteasome inhibitors in
anticancer drug design. Med Res Rev. 34:1001–1069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Wang X, Chen X, Yang X, Gao W, He B, Dai
W, Zhang H, Wang X, Wang J, Zhang X, et al: A nanomedicine based
combination therapy based on QLPVM peptide functionalized liposomal
tamoxifen and doxorubicin against Luminal A breast cancer.
Nanomedicine. 12:387–397. 2016. View Article : Google Scholar
|
|
215
|
Cheng T and Zhan X: Pattern recognition
for predictive, preventive, and personalized medicine in cancer.
EPMA J. 8:51–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Vadevoo SMP, Gurung S, Khan F, Haque ME,
Gunassekaran GR, Chi L, Permpoon U and Lee B: Peptide-based
targeted therapeutics and apoptosis imaging probes for cancer
therapy. Arch Pharm Res. 42:150–158. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Sun X, Li Y, Liu T, Li Z, Zhang X and Chen
X: Peptide-based imaging agents for cancer detection. Adv Drug
Deliv Rev. 110-111:38–51. 2017. View Article : Google Scholar :
|
|
218
|
Ehlerding EB, Sun L, Lan X, Zeng D and Cai
W: Dual-targeted molecular imaging of cancer. J Nucl Med.
59:390–395. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Wang Q, Li SB, Zhao YY, Dai DN, Du H, Lin
YZ, Ye JC, Zhao J, Xiao W, Mei Y, et al: Identification of a sodium
pump Na(+)/K(+) ATPase alpha1-targeted peptide for PET imaging of
breast cancer. J Control Release. 281:178–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Perez SA, von Hofe E, Kallinteris NL,
Gritzapis AD, Peoples GE, Papamichail M and Baxevanis CN: A new era
in anticancer peptide vaccines. Cancer. 116:2071–2080.
2010.PubMed/NCBI
|
